Aspen Pharmacare ROE 2017-2023 | APNHY

Current and historical return on equity (ROE) values for Aspen Pharmacare (APNHY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Aspen Pharmacare ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $5.172B $2.296B
Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $14.440B 5.21
Dr Reddy's Laboratories (RDY) India $12.040B 19.04
BridgeBio Pharma (BBIO) United States $4.408B 0.00
Bausch Health Cos (BHC) Canada $3.088B 2.41
Amphastar Pharmaceuticals (AMPH) United States $1.963B 13.44
Supernus Pharmaceuticals (SUPN) United States $1.626B 0.00
Taysha Gene Therapies (TSHA) United States $0.460B 0.00
Generation Bio (GBIO) United States $0.187B 0.00
Assembly Biosciences (ASMB) United States $0.072B 0.00
Personalis (PSNL) United States $0.064B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.026B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00